IRRAS (OM:IRRAS) - Prezzo delle azioni, notizie e analisi

IRRAS Panoramica delle azioni

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. Maggiori dettagli

IRRAS analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 62.97% all'anno

Analisi del rischio

Ha meno di 1 anno di pista di cassa

Non ha una capitalizzazione di mercato significativa ( SEK182M )

Non ha entrate significative ( SEK43M )

Gli azionisti sono stati diluiti nell'ultimo anno

+ 1 più rischio

IRRAS AB (publ) Concorrenti

Nanexa

OM:NANEXA

SEK 173.0m

Prolight Diagnostics

NGM:PRLD

SEK 103.9m

Luxbright

OM:LXB

SEK 105.9m

Phase Holographic Imaging PHI

NGM:PHI

SEK 169.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per IRRAS
Prezzi storici delle azioni
Prezzo attuale dell'azione	SEK 0.16
Massimo di 52 settimane	SEK 0.63
Minimo di 52 settimane	SEK 0.11
Beta	1.73
1Variazione di 1 mese	-6.47%
Variazione a 3 mesi	-10.39%
Variazione di 1 anno	-64.36%
3Variazione a 3 anni	-97.58%
Variazione a 5 anni	-99.58%
Variazione dall'IPO	-99.57%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	IRRAS	SE Medical Equipment	SE Mercato
7D	-1.1%	-5.8%	-2.4%
1Y	-64.4%	-7.8%	10.9%

Ritorno vs Industria: IRRAS ha avuto una performance inferiore rispetto al Swedish Medical Equipment che ha registrato un rendimento -7.8 % nell'ultimo anno.

Rendimento vs Mercato: IRRAS ha avuto una performance inferiore al mercato Swedish che ha registrato un rendimento 10.9 % nell'ultimo anno.

Volatilità dei prezzi

Is IRRAS's price volatile compared to industry and market?
IRRAS volatility
IRRAS Average Weekly Movement	5.7%
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Prezzo delle azioni stabile: IRRAS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di IRRAS è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2011	47	Will Martin	www.irras.com

IRRAS AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di IRRAS con la sua capitalizzazione di mercato?
IRRAS statistiche fondamentali
Capitalizzazione di mercato	SEK 181.75m
Guadagni(TTM)	-SEK 196.40m
Ricavi(TTM)	SEK 43.10m

4.2x

Rapporto P/S

-0.9x

Rapporto P/E

IRRAS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IRRAS Conto economico (TTM)
Ricavi	SEK 43.10m
Costo del fatturato	SEK 44.03m
Profitto lordo	-SEK 935.00k
Altre spese	SEK 195.47m
Guadagni	-SEK 196.40m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

Feb 21, 2024

Utile per azione (EPS)	-0.17
Margine lordo	-2.17%
Margine di profitto netto	-455.71%
Rapporto debito/patrimonio netto	0%

Come si è comportato IRRAS nel lungo periodo?

Vedi performance storica e confronto

IRRAS Panoramica delle azioni

Premi

Analisi del rischio

IRRAS AB (publ) Concorrenti

OM:NANEXA

SEK 173.0m

NGM:PRLD

SEK 103.9m

OM:LXB

SEK 105.9m

NGM:PHI

SEK 169.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00